What the FDA labels say about taking them together
Pregabalin and remifentanil
Remifentanil's FDA label of December 15, 2025 names pregabalin in its drug interactions section; pregabalin's label does not name remifentanil itself but warns about its class (Opioids (opioid agonists)). The remifentanil label: “Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants including alcohol, increases the risk of hypotension, respiratory depression, profound sedation, coma, and death.”
Check it at the source: the pregabalin FDA label on DailyMed (effective April 15, 2025, Viatris Specialty LLC); the remifentanil FDA label on DailyMed (effective December 15, 2025, Mylan Institutional LLC).
What does the pregabalin label say about remifentanil?
Pregabalin's label does not name remifentanil itself; it warns about its class (Opioids (opioid agonists)):
Pregabalin label, warnings and precautionsThere is evidence from case reports, human studies, and animal studies associating LYRICA with serious, life-threatening, or fatal respiratory depression when co-administered with central nervous system (CNS) depressants, including opioids, or in the setting of underlying respiratory impairment.
Pregabalin label, warnings and precautionsWhen the decision is made to co-prescribe LYRICA with another CNS depressant, particularly an opioid, or to prescribe LYRICA to patients with underlying respiratory impairment, monitor patients for symptoms of respiratory depression and sedation, and consider initiating LYRICA at a low dose.
Source: FDA drug label (Lyrica), NDA021446 (Upjohn), as published by Viatris Specialty LLC, effective April 15, 2025 (SPL set d4734e7d-5079-455e-8ff5-8f4539c998a9), via openFDA; the full label on DailyMed
What does the remifentanil label say about pregabalin?
Remifentanil label, drug interactionsBenzodiazepines and other Central Nervous System (CNS) Depressants Clinical Impact: Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants including alcohol, increases the risk of hypotension, respiratory depression, profound sedation, coma, and death. … anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids (gabapentin or pregabalin), other opioids, alcohol.
Remifentanil label, warnings and precautionsHypotension, profound sedation, respiratory depression, coma, and death may result from the concomitant use of ULTIVA with benzodiazepines and/or other CNS depressants, including alcohol (e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids [gabapentin and pregabalin], and other opioids).
Source: FDA drug label (Ultiva), Mylan Institutional LLC, effective December 15, 2025 (SPL set 4dbcb8f9-1987-4b66-bd2f-d251fda0be10), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Pregabalin | Remifentanil | |
|---|---|---|
| Labeled for | Nerve pain and fibromyalgia, Seizures and epilepsy | n/a |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.0571 per capsule 100 mg capsule | n/a |
| Shortage now | No current entry | In shortage |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once